3 Healthcare Stock Stories for Thursday Enjoyment

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

StemCells (NASDAQ:STEM): Closing price $

On Thursday, the firm announced that it has reached an agreement with the California Institute for Regenerative Medicine through which CIRM will provide around $19.3 million to help fund preclinical development and IND-enabling activities of the Company’s proprietary HuCNS-SC product candidate (purified human neural stem cells) for Alzheimer’s disease. The funding, which will be in the form of a forgivable loan, was awarded under CIRM’s Disease Team Therapy Development Award program (RFA 10-05) in September of 2012. The goal of the research will be to file an Investigational New Drug application with the FDA within four years.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

STEM

ACADIA Pharmaceuticals  (NASDAQ:ACAD): Closing price $

The company reported that the FDA has agreed that the data from the pivotal Phase III -020 study, along with supportive data from other evaluations with pimavanserin, are sufficient to support the filing of a New Drug Application (NDA) for the treatment of Parkinsons disease psychosis . Thus, ACADIA will no longer conduct the Phase III -021 study that was planned as a confirmatory trial and was set to be initiated later in April. ACADIA is a biopharmaceutical firm focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ACAD

Medtronic (NYSE: MDT) Closing price $

Medtronic on Thursday reported the first patient enrollments in the SubQStim II pivotal clinical trial to pursue FDA approval of peripheral nerve stimulation, also known as subcutaneous nerve stimulation, for the reduction of chronic, intractable post-surgical back pain. PNS involves an implant of electrical leads just under the skin of the lower back. These leads are connected to a stimulator which delivers mild electrical impulses to the nerves, interrupting pain signals traveling through the nervous system to the brain. Medtronic received CE Mark for the first 16-electrode, fully implantable system for the percutaneous delivery of PNS in the management of chronic back pain in May of 2011.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

MDT

Don’t Miss: Would Obama’s Budget Make a Healthcare Workforce Crisis Worse?

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business